Adma Biologics (ADMA ... Shares of the infectious disease drug developer witnessed a loss of 3.02% over the previous month, trailing the performance of the Medical sector with its gain of 5. ...

Adma Biologics shares have fallen roughly 8% since the beginning of the year. In the final minutes of trading on Monday, shares hit $15.83, nearly tripling in the last 12 months.

Sees FY26 adjusted EBITDA at least $305M. Sees FY26 adjusted net income at least $235M. Grossman concluded, “Looking ahead, these strengthened ...

Total Revenue of $426.5 Million, a 65% YoY IncreaseFY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation ...

ADMA Biologics, Inc. ( NASDAQ: ADMA) Q4 2024 Earnings Conference Call March 3, 2025 4:30 PM ET Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - Founder, ...

The infectious disease drug developer posted revenue of $117.5 ... Revenue was reported as $426.5 million. Adma Biologics shares have dropped nearly 8% since the beginning of the year.